

Paul C Langley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6746238/publications.pdf>

Version: 2024-02-01

41
papers

701
citations

687220

13
h-index

552653

26
g-index

41
all docs

41
docs citations

41
times ranked

591
citing authors

#	ARTICLE	IF	CITATIONS
1	Nothing to Cheer About: Endorsing Imaginary Economic Evaluations and Value Claims with CHEERS 22. F1000Research, 2022, 11, 248.	0.8	5
2	Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience. Innovations in Pharmacy, 2021, 12, 5.	0.2	5
3	Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims. Innovations in Pharmacy, 2021, 12, 11.	0.2	2
4	Fundamental Measurement and Quality-Adjusted Life Years. Value in Health, 2021, 24, 461.	0.1	5
5	Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure. Innovations in Pharmacy, 2021, 12, 6.	0.2	11
6	Fundamental Outcome Measurement: Selecting Patient Reported Outcome Instruments and Interpreting the Data they Produce. Innovations in Pharmacy, 2021, 12, 17.	0.2	6
7	Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment. Innovations in Pharmacy, 2021, 12, 20.	0.2	7
8	The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment. Pharmacy (Basel, Switzerland), 2020, 8, 119.	0.6	0
9	Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 689-695.	0.5	6
10	Nonsense on Stilts – Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds. Innovations in Pharmacy, 2020, 11, 12.	0.2	14
11	The Great I-QALY Disaster. Innovations in Pharmacy, 2020, 11, 7.	0.2	13
12	Value Assessment in Cystic Fibrosis: ICER’s Rejection of the Axioms of Fundamental Measurement. Innovations in Pharmacy, 2020, 11, 8.	0.2	1
13	Measurement, modeling and QALYs. F1000Research, 2020, 9, 1048.	0.8	16
14	To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims. Innovations in Pharmacy, 2020, 11, 22.	0.2	1
15	The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). Innovations in Pharmacy, 2020, 11, .	0.2	0
16	Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines. Innovations in Pharmacy, 2020, 11, .	0.2	4
17	The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER). Innovations in Pharmacy, 2020, 11, 17.	0.2	0
18	Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines. Innovations in Pharmacy, 2020, 11, 12.	0.2	6

#	ARTICLE	IF	CITATIONS
19	A Practice Based Behavioral Health Management Registry (BHMR): Implementation, Structure and Content. <i>Innovations in Pharmacy</i> , 2019, 10, 3.	0.2	2
20	Tracking and Reporting Outcomes in Medical Marijuana: Establishing Condition Specific State Level Registries. <i>Innovations in Pharmacy</i> , 2019, 10, 4.	0.2	1
21	Na domhain shamhlaíochta: formulary submission guidelines in Ireland and the standards of normal science. <i>Current Medical Research and Opinion</i> , 2016, 32, 1641-1644.	0.9	11
22	Nullius in verba: The University of Minnesota Social and Administrative Pharmacy Program proposed Guidelines for Formulary Evaluations. <i>Innovations in Pharmacy</i> , 2016, 7, .	0.2	10
23	The status of modeled claims. <i>Journal of Medical Economics</i> , 2015, 18, 991-992.	1.0	8
24	Validation of modeled pharmacoeconomic claims in formulary submissions. <i>Journal of Medical Economics</i> , 2015, 18, 993-999.	1.0	33
25	Time since diagnosis, treatment pathways and current pain status: a retrospective assessment in a back pain population. <i>Journal of Medical Economics</i> , 2013, 16, 701-709.	1.0	5
26	The societal burden of pain in Germany: Health-related quality-of-life, health status and direct medical costs. <i>Journal of Medical Economics</i> , 2012, 15, 1201-1215.	1.0	30
27	The impact of rheumatoid arthritis on the burden of disease in urban China. <i>Journal of Medical Economics</i> , 2011, 14, 709-719.	1.0	28
28	The prevalence, correlates and treatment of pain in Spain. <i>Journal of Medical Economics</i> , 2011, 14, 367-380.	1.0	79
29	The association of pain with labor force participation, absenteeism, and presenteeism in Spain. <i>Journal of Medical Economics</i> , 2011, 14, 835-845.	1.0	18
30	The societal impact of pain in the European Union: health-related quality of life and healthcare resource utilization. <i>Journal of Medical Economics</i> , 2010, 13, 571-581.	1.0	97
31	The impact of pain on labor force participation, absenteeism and presenteeism in the European Union. <i>Journal of Medical Economics</i> , 2010, 13, 662-672.	1.0	104
32	A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts. <i>Journal of Medical Economics</i> , 2010, 13, 1-7.	1.0	20
33	Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?. <i>Current Medical Research and Opinion</i> , 2004, 20, 181-188.	0.9	9
34	Treatment of Pneumonias in a Managed-Care Organisation. <i>Disease Management and Health Outcomes</i> , 1999, 6, 159-173.	0.3	4
35	Formulary Submission Guidelines for Blue Cross and Blue Shield of Colorado and Nevada. <i>Pharmacoeconomics</i> , 1999, 16, 211-224.	1.7	17
36	Peripheral Vascular Disorders. <i>Pharmacoeconomics</i> , 1997, 11, 225-236.	1.7	8

#	ARTICLE	IF	CITATIONS
37	Cost Effectiveness and Allocation of Therapies in a Treating Population: The Author's Reply. <i>Pharmacoeconomics</i> , 1997, 11, 606-608.	1.7	0
38	Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 1185-1190.	0.5	37
39	The November 1995 Revised Australian Guidelines for the Economic Evaluation of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1996, 9, 341-352.	1.7	38
40	Cost Effectiveness and the Allocation of Therapies in a Treating Population. <i>Pharmacoeconomics</i> , 1996, 10, 93-98.	1.7	7
41	Disease Management Programs. <i>American Journal of Health-System Pharmacy</i> , 1996, 53, 53-58.	0.5	33